I am delighted to share an update on the strong performance of Evergrowth BioHealthcare Capital. Since inception, the fund has delivered gross returns exceeding 83%, and year-to-date through December 2025, we have achieved gross returns over 24%. These outstanding results reflect the disciplined and research-driven strategy.
As Christmas and the New Year draw near, my team and I extend our warmest wishes to you and your loved ones. May the season bring you abundant wealth, robust health, and profound happiness.
We remain fully committed to delivering superior risk-adjusted returns in the dynamic biotech and healthcare landscape.
Wishing you a Merry Christmas and a prosperous 2026 and beyond.
To your health, retirement, and superior returns,
Harvey Tran, MD | Chief Investment Officer, Evergrowth BioHealthcare Capital
Join our Skool community page at https://www.skool.com/evergrowthbiohealthcarecapital
Schedule a free consultation with me to see if we are the right fit https://calendly.com/drharveytran/evergrowth-introduction?month=2025-05.
You can check out our Fund Presentation below:
Follow me on Social Media:
Enjoyed This? Stick Around! Subscribe to my newsletter for more insights on using your MD advantage in biotech investing.
Check out our Fund Presentation and our Skool Community Page.
More Reads for You:
- Exceptional Performance and Holiday Greetings
- Why I Prefer Fundamentals Over Charts: A Physician-Investor’s Perspective on Long-Term Investing
- An Integrated BioSci Investing Approach for Alpha Returns
- Welcoming Dr. Victoria Mondloch to the Evergrowth Medical Advisory Board
- Stop Trading Stocks, Start Owning Businesses
- The Case for Long-Term Biotech Investing: My Story with Jazz Pharmaceuticals
